Plecanatide Research: What 133 Studies Show (2026) | RetatrutideCompare

Plecanatide — 133 studies indexed on PubMed. Guanylate cyclase-C agonist (uroguanylin-like, pH-sensitive activity in proximal small intestine). Half-life: Negligible systemic absorption. FDA status: FDA-approved (2017).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Plecanatide?

There are approximately 133 studies indexed on PubMed that mention Plecanatide (Trulance), based on a search last updated 2026-06-18.

Is Plecanatide FDA-approved?

FDA status: FDA-approved (2017).

How does Plecanatide work?

Guanylate cyclase-C agonist (uroguanylin-like, pH-sensitive activity in proximal small intestine).

Guanylate cyclase-C agonist (uroguanylin-like, pH-sensitive activity in proximal small intestine).

Reference facts

Also known as
Trulance
Category
Gastrointestinal
Mechanism of action
Guanylate cyclase-C agonist (uroguanylin-like, pH-sensitive activity in proximal small intestine).
Targets
GC-C receptor
Indications under research or approved
Chronic idiopathic constipation, IBS-C
Regulatory status (reference entry)
FDA-approved (2017)
Half-life
Negligible systemic absorption
Sequence
NDECELCVNVACTGCL
Sequence notes
16-residue uroguanylin analog with two disulfide bonds; oral, gut-restricted.
Molecular weight (Da)
1682
Originator / sponsor
Salix / Bausch Health
First reported
2010

Primary References

Explore research articles about Plecanatide

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.